Why Your FDA Equivalence Logic Fails Under MDR
A manufacturer submitted a clinical evaluation using substantial equivalence from their FDA 510(k) clearance. The Notified Body rejected it in the first review. The clinical team was confused. They had three predicate devices. They had performance data. They had comparative testing. Everything looked solid. But they were solving the wrong equivalence problem.
In This Article
This happens more often than it should. Teams experienced with FDA submissions assume equivalence works the same way under MDR. It does not.
The confusion is understandable. Both frameworks use the term equivalence. Both compare your device to other devices. Both require clinical data. But the logic, the burden, and the regulatory consequence are fundamentally different.
Understanding this difference is not academic. It determines whether your clinical evaluation will survive Notified Body review.
The FDA Logic: Substantial Equivalence
Under FDA 510(k), substantial equivalence means your device is as safe and effective as a legally marketed predicate device. You identify a predicate. You compare intended use, technological characteristics, and performance. If the differences do not raise new questions of safety and effectiveness, you demonstrate equivalence.
This is a comparison of regulatory status. The predicate device is already cleared. Your burden is to show you are not meaningfully different in ways that matter for risk.
The focus is on similarity. The standard is not raising new concerns.
You can use non-clinical testing. You can use literature. You can use performance data. Clinical studies are rarely required unless differences introduce new risk questions.
This is a streamlined pathway. It works because the FDA has already reviewed and accepted the predicate device.
The MDR Logic: Equivalence for Clinical Data
Under MDR Article 61 and MDCG 2020-5, equivalence is not about regulatory status. It is about borrowing clinical data from another device to support the safety and performance of your device.
The equivalent device does not need to be cleared or approved by any authority. It only needs to have sufficient clinical data that is relevant to your device.
The comparison is technical and clinical. You are asking: Is this other device similar enough that its clinical data can reasonably predict the clinical performance of my device?
This is a much stricter test.
FDA equivalence compares regulatory paths. MDR equivalence compares clinical data validity. They answer different questions.
Why FDA Predicates Often Fail MDR Equivalence
A device that qualifies as a 510(k) predicate may not qualify as an MDR equivalent device. The reasons are structural.
First, MDR requires demonstration of equivalence in clinical, biological, and technical characteristics. Not just intended use and technological features. The standard is higher.
Second, you must have access to sufficient clinical data from the equivalent device. A 510(k) summary does not provide this. You need detailed clinical evidence. If the equivalent device manufacturer does not share data, the equivalence route collapses.
Third, any difference in materials, design, energy delivery, or mechanism of action can break equivalence under MDR. Under FDA, those differences may be acceptable if you show they do not raise new safety questions. Under MDR, they require clinical data specific to your device.
Fourth, MDR does not care if the equivalent device is legally marketed. It only cares if the clinical data from that device is valid and transferable. This inverts the FDA assumption.
Most FDA predicate strategies fail on point two and three. The predicate exists. The clearance exists. But the clinical data is either unavailable or insufficient to meet MDCG 2020-5 requirements.
Manufacturers reference their FDA predicate as the equivalent device without verifying access to full clinical data. The Notified Body requests the data. The manufacturer cannot provide it. The equivalence claim collapses.
What MDCG 2020-5 Actually Requires
MDCG 2020-5 defines equivalence through three pillars: clinical, technical, and biological characteristics. All three must align.
Clinical equivalence means same intended use, same clinical indication, same patient population, same body site, same duration of use. Any deviation requires justification and may require supplementary data.
Technical equivalence means same design, materials, specifications, deployment method, and mechanism of action. Differences in software, energy levels, or structural design typically break equivalence.
Biological equivalence means same interaction with tissues, same materials in contact with the body, same degradation profile if applicable. Even minor material differences can disqualify equivalence.
If you cannot demonstrate all three, you cannot use the equivalent device’s clinical data. You need your own clinical evidence.
This is not negotiable. MDCG 2020-5 is explicit. Notified Bodies follow it closely.
I have seen teams spend months building an equivalence argument only to abandon it when they realized they could not meet the technical or biological criteria. They had the FDA clearance. They had the predicate. But they did not have equivalence under MDR.
Access to Clinical Data: The Hidden Barrier
Even if the devices are technically and clinically equivalent, you must access the clinical data from the equivalent device. Not summaries. Not conclusions. Actual datasets, study reports, and follow-up data.
If the equivalent device is from another manufacturer, this requires a formal agreement. Most manufacturers will not share detailed clinical data. It exposes proprietary design, reveals clinical outcomes, and creates liability exposure.
If you cannot access the data, you cannot demonstrate equivalence.
This is the single most common failure point. Teams identify an equivalent device on the market. They analyze the technical files. They document clinical similarity. Then they discover the data is not accessible.
At that point, the clinical evaluation strategy must shift. You need clinical studies, literature, or post-market data specific to your device. The timeline extends. The budget increases. And the regulatory pathway changes.
Before committing to an equivalence-based clinical evaluation, verify access to full clinical datasets. If you cannot access the data, the strategy is not viable.
When Equivalence Works Under MDR
Equivalence under MDR works in specific situations. Same manufacturer. Same design lineage. Controlled modifications. Shared clinical data.
If you are upgrading your own device, you may use your previous generation as the equivalent device. You have access to the clinical data. You control the technical documentation. You can demonstrate continuity in design.
If you license a device from another manufacturer and the agreement includes full clinical data access, equivalence may be viable. But this must be explicit in the contract.
If you are part of a corporate group with multiple devices in the same family, internal data sharing can support equivalence. But the technical, clinical, and biological alignment must still be demonstrated.
Outside these scenarios, equivalence is difficult. It requires alignment of incentives, legal agreements, and technical rigor that most cross-company relationships cannot support.
What This Means for Your Clinical Strategy
If your clinical evaluation relies on FDA substantial equivalence, review it against MDCG 2020-5 requirements. Ask three questions.
First, do you have access to full clinical data from the equivalent device? Not regulatory summaries. Actual study reports.
Second, can you demonstrate equivalence in all three domains: clinical, technical, and biological? Document every similarity. Justify every difference. If any difference is material, equivalence may not hold.
Third, does the Notified Body agree with your equivalence assessment? This is not rhetorical. Equivalence is a judgment call. Notified Bodies apply MDCG 2020-5 strictly. What seems equivalent to you may not meet their threshold.
If any answer is uncertain, consider alternative clinical strategies. Literature-based evaluation. Clinical studies. Post-market surveillance data. These paths take longer, but they do not collapse under data access issues.
Equivalence is a tool. But it is not always the right tool.
Manufacturers assume their FDA predicate automatically qualifies as an MDR equivalent device. They build the entire clinical evaluation on this assumption. Then the Notified Body challenges the equivalence claim. The submission stalls. The timeline collapses. The clinical strategy must be rebuilt from the start.
Final Thought
The words are the same. The concept feels similar. But substantial equivalence and MDR equivalence solve different problems.
FDA equivalence is about regulatory clearance. MDR equivalence is about clinical data validity.
One gets you market access in the US. The other supports a safety and performance argument in the EU.
Confusing the two creates risk. It delays timelines. It forces rework. And it exposes gaps that could have been addressed earlier.
Review your clinical evaluation strategy. Make sure you are answering the right equivalence question.
In the next part of this series, we will examine how FDA post-market surveillance compares to MDR PMCF requirements. The terminology overlaps. The execution does not.
Frequently Asked Questions
What is a Clinical Evaluation Report (CER)?
A CER is a mandatory document under MDR 2017/745 that demonstrates the safety and performance of a medical device through systematic analysis of clinical data. It must be updated throughout the device lifecycle based on PMCF findings.
How often should the CER be updated?
The CER should be updated whenever significant new clinical data becomes available, after PMCF activities, when there are changes to the device or intended purpose, and at minimum during annual reviews as part of post-market surveillance.
What causes CER rejection by Notified Bodies?
Common reasons include inadequate equivalence demonstration, insufficient clinical data for claims, poorly structured SOTA analysis, missing gap analysis, and lack of clear benefit-risk determination. Structure and logical flow are as important as the data itself.
Which MDCG guidance documents are most relevant for clinical evaluation?
Key documents include MDCG 2020-5 (Equivalence), MDCG 2020-6 (Sufficient Clinical Evidence), MDCG 2020-13 (CEAR Template), MDCG 2020-7 (PMCF Plan), and MDCG 2020-8 (PMCF Evaluation Report). MDR Article 61, MDCG 2020-5
Need Expert Help with Your Clinical Evaluation?
Get personalized guidance on MDR compliance, CER writing, and Notified Body preparation.
✌
Peace, Hatem
Your Clinical Evaluation Partner
Follow me for more insights and practical advice.
– Regulation (EU) 2017/745 (MDR), Article 61
– MDCG 2020-5: Clinical Evaluation – Equivalence
Deepen Your Knowledge
Read Complete Guide to Clinical Evaluation under EU MDR for a comprehensive overview of clinical evaluation under EU MDR 2017/745.
